Hamad Alsuhaibani,MD KING FAISAL SPECIALIST HOSPITAL &RESEARCH CENTRE.
|
|
- Shona Underwood
- 5 years ago
- Views:
Transcription
1 Hamad Alsuhaibani,MD KING FAISAL SPECIALIST HOSPITAL &RESEARCH CENTRE.
2 YTTRIUM-90( 90 Y) TRANSARTERIAL HEPATIC RADIOEMBOLIZATION FOR HEPATOCELLULAR CARCINOMA EFFICACY AND SAFETY OF YTTRIUM-90 RADIO- EMBOLIZATION FOR THE TREATMENT OF HEPATOCELLULAR CARCINOMA, a single center experience Hamad Alsuhaibani, Abdulmajeed Al Hazzani, Mohammed Al Sebayel, Almoutaz Hashim, Waleed Al Hamoudi, Hamad Al Bahili, Hussien ElSiesy, Faisal Aba AlKhail Department of Radiology and Department of Liver Transplantation, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia
3 YTTRIUM-90( 90 Y) TRANSARTERIAL HEPATIC RADIOEMBOLIZATION FOR HEPATOCELLULAR CARCINOMA Locoregional transarterial treatment Uses Yettrium90 (90Y) loaded on Microcepheres Gives high dose of radiation to the tumor with relative sparing of liver parenchyma Applicable to BCLC intermediate stage(b) or stages(0) and (A) if not candidate for curative treatments
4
5 YTTRIUM-90( 90 Y) TRANSARTERIAL HEPATIC RADIOEMBOLIZATION FOR HEPATOCELLULAR CARCINOMA Indications: Palliative Treatment Downstaging for Curative Treatment; RFA, Resection, Transplantation. Bridging to Transplantation.
6 YTTRIUM-90( 90 Y) TRANSARTERIAL HEPATIC RADIOEMBOLIZATION FOR HEPATOCELLULAR CARCINOMA Inclusion Criteria: Multidisciplinary tumor board Non-infiltrative tumor Not treatable by other modalities No extrahepatic disease Tumor burden < 50% Should fulfill criteria for Okuda stage 1, CLIP 2 or Child-Pugh Class A or early B Life expectancy >3 months Performance Status 0-1.
7 YTTRIUM-90( 90 Y) TRANSARTERIAL HEPATIC RADIOEMBOLIZATION FOR HEPATOCELLULAR CARCINOMA KFSH&RC Experience Retrospective review of patients done from January, 2008 to December, 2012 Eighty Eight HCC patients were treated ( 55 M & 33 F) Ninety Nine Treatment Sessions(1.12/pt) Age range y ( Mean 63 y) Portal Vein Thrombosis, Nine (9) Patients Follow up between 1-53 months( Mean 16.5 months)
8 YTTRIUM-90( 90 Y) TRANSARTERIAL HEPATIC RADIOEMBOLIZATION FOR HEPATOCELLULAR CARCINOMA Results1: KFSH&RC Experience No procedure-related complications Thirty days mortality=0 No pulmonary or GI complications Mild post embolization syndrome (Outpatient procedure)
9 YTTRIUM-90( 90 Y) TRANSARTERIAL HEPATIC RADIOEMBOLIZATION FOR HEPATOCELLULAR CARCINOMA Results2: Liver function; KFSH&RC Experience Stable: 58 (66%) patients Mild, mostly transient: 23(26%) patients Moderate: 5(5.7%) patients 4 died ( 2, 3m. 1, 5m, 1, 21m) Sever: 2(2.2%) patients, both died at 4 and 11.5 months post treatment.
10 YTTRIUM-90( 90 Y) TRANSARTERIAL HEPATIC RADIOEMBOLIZATION FOR HEPATOCELLULAR CARCINOMA Results3: Eleven ( 11) Patients underwent liver transplantation All are alive KFSH&RC Experience Histology available for 8 Patients( 9 tumors) No significant necrosis: % necrosis: % necrosis: 3 Complete necrosis: 2
11 YTTRIUM-90( 90 Y) TRANSARTERIAL HEPATIC RADIOEMBOLIZATION FOR HEPATOCELLULAR CARCINOMA KFSH&RC Experience Radiological Response Modified RECIST (mrecist) Complete Response(CR), Disappearance of any intratumoral enhancement in all target lesions Partial Response(PR), At least a 30% decrease in the sum of diameters of viable (enhancing) target lesions Stable Disease(SD), Any cases that do not qualify for either partial response or progressive disease Progressive Disease(PD), An increase of at least 20% in the sum of the viable (enhancing) target lesions
12 YTTRIUM-90( 90 Y) TRANSARTERIAL HEPATIC RADIOEMBOLIZATION FOR HEPATOCELLULAR CARCINOMA Results4: KFSH&RC Experience Radiological Response Available for 70(79%) patients CR 32 ( 46%) PR 17 ( 24%) SD 13 ( 18%) PD 8 ( 11%) Objective Response( CR+PR) 70%
13 YTTRIUM-90( 90 Y) TRANSARTERIAL HEPATIC RADIOEMBOLIZATION FOR HEPATOCELLULAR CARCINOMA Results5: KFSH&RC Experience Survival Data (Median survival) Overall : 30 months Without Portal Vein Thrombosis(PVT): 30 months With PVT: 11.5 months
14 Group Patients (n) Survival Median (95% CI) P Overall ( ) PVT Absent ( ) PVT Present (nc* ) *nc not calculable
15 Cum Survival HCC, Post Y90 Treatment at KFSH&RC Overall Survival Survival Function 1.0 Survival Function Censored F/U MONTH
16 Cum Survival HCC, Post Y90 Treatment at KFSH&RC Survival Functions PVT NO YES NO-censored YES-censored F/U MONTH
17 Conclusion: Treatment of appropriately selected HCC patients with Y 90 microsphere as locoregional therapy is effective and safe and is likely to improve patient s survival.
18 Pre 90 Y Case 1 82Y M HCC 4M 10M 19M Post 90 Y 4M 10M19M
19 Case 2 70 Y, M HCC Pre Y 90 Post Y 90 4M
20 HCC Case 3, 73 y, M Pre Y90 Post Y90 12M
21 HCC Case 4, 44 Y M, SEG#5 HCC+ PVT Pre Y 90 Post Y 90 7M11 2MM
22 Case 5, 56y, F Pre Y90 HCC Pre Y90
23 Tumor Necrosis- Gross appearance
24 Normal Hepatocytes Hepatocellular Carcinoma
25 Tumor Necrosis 2 Microsphere
26 Case 6 77y, M HCC Pre Y90 Post Y90 11M 37M
27 Case 7, 75y,M, Two Tx HCC Pre Y-90 Post Y-90 8M 17M
28 Case 7, 75y,M, Two Tx HCC Pre Y-90 Post Y-90 8M 17M
29 Case 8 59y, F HCC Pre Y90 Post Y90 12M
30 HCC Case 9 61,M Pre Y90 Post Y90 3 M
31 HCC Case 10 69, M Pre Y90 Post Y90 3 M 3 M
32 HCC Case 11 69,F Pre Y90 Post Y90 1M
33
34 Group Patients (n) Survival Median (95% CI) P Overall ( ) Female ( ) Male ( ) *nc not calculable
35 Cum Survival HCC, Post Y90 Treatment at KFSH&RC Survival Functions GENDER F M F-censored M-censored F/U MONTH
The Egyptian Journal of Hospital Medicine (October 2017) Vol.69(1), Page
The Egyptian Journal of Hospital Medicine (October 2017) Vol.69(1), Page 1674-1679 Radioembolization in Treatment of Hepatocellular Carcinoma with Portal Vein Invasion Elsahhar Ahmed Hetta, Osama Mohamed
More informationGuidelines for SIRT in HCC An Evolution
Guidelines for SIRT in HCC An Evolution 2 nd Asia Pacific Symposium on Liver- Directed Y-90 Microspheres Therapy 1st November 2014, Singapore The challenge of HCC Surgery is potentially curative in early
More informationWHAT IS THE BEST APPROACH FOR TRANS-ARTERIAL THERAPY IN HCC?
WHAT IS THE BEST APPROACH FOR TRANS-ARTERIAL THERAPY IN HCC? Dr. Alexander Kim Chief, Vascular and Interventional Radiology, Medstar Georgetown University Hospital, USA DISCLAIMER Please note: The views
More informationSelection Criteria and Insertion of SIRT into HCC Treatment Guidelines
Selection Criteria and Insertion of SIRT into HCC Treatment Guidelines 2 nd Asia Pacific Symposium on Liver- Directed Y-90 Microspheres Therapy 1st November 2014, Singapore Pierce Chow FRCSE PhD SIRT in
More informationHepatocellular Carcinoma: A major global health problem. David L. Wood, MD Interventional Radiology Banner Good Samaritan Medical Center
Hepatocellular Carcinoma: A major global health problem David L. Wood, MD Interventional Radiology Banner Good Samaritan Medical Center Hepatocellular Carcinoma WORLDWIDE The #2 Cancer Killer Overall cancer
More informationTrans-arterial radioembolisation (TARE) of unresectable HCC using Y-90 microspheres: is it dangerous in case of portal vein thrombosis?
Trans-arterial radioembolisation (TARE) of unresectable HCC using Y-90 microspheres: is it dangerous in case of portal vein thrombosis? Poster No.: C-1634 Congress: ECR 2014 Type: Authors: Keywords: DOI:
More informationLocoregional Treatments for HCC Applications in Transplant Candidates. Locoregional Treatments for HCC Applications in Transplant Candidates
Locoregional Treatments for HCC Applications in Transplant Candidates Matthew Casey, MD March 31, 2016 Locoregional Treatments for HCC Applications in Transplant Candidates *No disclosures *Off-label uses
More informationUnmet needs in intermediate HCC. Korea University Guro Hospital Ji Hoon Kim
Unmet needs in intermediate HCC Korea University Guro Hospital Ji Hoon Kim BCLC HCC Stage 0 PST 0, Child Pugh A Stage A C PST 0 2, Child Pugh A B Stage D PST > 2, Child Pugh C Very early stage (0) 1 HCC
More informationMULTI-DISCIPLINARY MANAGEMENT OF INTERMEDIATE STAGE HCC
Dr Apoorva Gogna MBBS FRCR FAMS Consultant Interventional Radiology Center Department of Diagnostic Radiology SingaporeGeneral Hospital MULTI-DISCIPLINARY MANAGEMENT OF INTERMEDIATE STAGE HCC CASE HISTORY
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE INTERVENTIONAL PROCEDURES PROGRAMME Interventional procedure overview of selective internal radiation therapy for primary liver cancer Selective internal
More informationLocoregional Therapy for Hepatoma
Locoregional Therapy for Hepatoma Robert D. Crane, MD Interventional Radiology Virginia Mason How do we know a liver mass is HCC? HCC : Bx Of pts getting liver transplant only ~ 5% had Bx to establish
More informationHepatocellular Carcinoma: Diagnosis and Management
Hepatocellular Carcinoma: Diagnosis and Management Nizar A. Mukhtar, MD Co-director, SMC Liver Tumor Board April 30, 2016 1 Objectives Review screening/surveillance guidelines Discuss diagnostic algorithm
More informationInterventional Radiology in Liver Cancer. Nakarin Inmutto MD
Interventional Radiology in Liver Cancer Nakarin Inmutto MD Liver cancer Primary liver cancer Hepatocellular carcinoma Cholangiocarcinoma Metastasis Interventional Radiologist Diagnosis Imaging US / CT
More information6/16/2016. Treating Hepatocellular Carcinoma: Deciphering the Clinical Data. Liver Regeneration. Liver Regeneration
Treating : Deciphering the Clinical Data Derek DuBay, MD Associate Professor of Surgery Director of Liver Transplant Liver Transplant and Hepatobiliary Surgery UAB Department of Surgery Liver Regeneration
More informationSIRT for Intermediate and Advanced HCC
Pamplona, junio de 2008 SIRT for Intermediate and Advanced HCC Bruno Sangro Clínica Universidad de Navarra. CIBERehd. Pamplona, Spain 90 Y-RE MRI SPECT FUSION 90 Y-RE = Yttrium-90 radioembolization Sangro
More informationSEQUENCING OF HCC TREATMENT. Dr. Amit G. Singal Medical Director, UT Southwestern Medical Center, USA
SEQUENCING OF HCC TREATMENT Dr. Amit G. Singal Medical Director, UT Southwestern Medical Center, USA February 2018 DISCLAIMER Please note: The views expressed within this presentation are the personal
More informationRadioembolization for Primary and Metastatic Tumors of the Liver
Page: 1 of 28 Last Review Status/Date: September 2015 Description Radioembolization (RE), also referred to as selective internal radiotherapy (SIRT), is the intra-arterial delivery of small beads (microspheres)
More informationRadioembolization for Primary and Metastatic Tumors of the Liver
Radioembolization for Primary and Metastatic Tumors of the Liver Policy Number: 8.01.43 Last Review: 8/2017 Origination: 8/2006 Next Review: 8/2018 Policy Blue Cross and Blue Shield of Kansas City (Blue
More informationDescription. Section: Therapy Effective Date: July 15, 2014 Subsection: Therapy Original Policy Date: June 7, 2012 Subject: Page: 1 of 23
Last Review Status/Date: June 2014 Page: 1 of 23 Description Radioembolization (RE), referred to as selective internal radiation therapy or SIRT in older literature, is the intra-arterial delivery of small
More informationHepatocellular carcinoma with macrovascular invasion treated with yttrium-90 radioembolization prior to transplantation
Original rticle Hepatocellular carcinoma with macrovascular invasion treated with yttrium-90 radioembolization prior to transplantation Giovanni attista Levi Sandri 1, Giuseppe Maria Ettorre 1, Marco Colasanti
More informationInterventional Radiologic Treatment of Hepatocellular Carcinoma
Interventional Radiologic Treatment of Hepatocellular Carcinoma Fatih Boyvat Abstract The current treatment modalities for patients with hepatocellular carcinoma are discussed in this review. Hepatocellular
More informationLiver resection for HCC
8 th LIVER INTEREST GROUP Annual Meeting Cape Town 2017 Liver resection for HCC Jose Ramos University of the Witwatersrand Donald Gordon Medical Centre The liver is almost unique in that treatment of the
More informationSelective internal radiation therapy using yttrium-90 resin microspheres in patients with unresectable hepatocellular carcinoma: a retrospective study
Original Article Selective internal radiation therapy using yttrium-90 resin microspheres in patients with unresectable hepatocellular carcinoma: a retrospective study Parvez S. Mantry 1, Ashwini Mehta
More informationSurveillance for Hepatocellular Carcinoma
Surveillance for Hepatocellular Carcinoma Marion G. Peters, MD John V. Carbone, MD, Endowed Chair Professor of Medicine Chief of Hepatology Research University of California San Francisco Recorded on April
More informationSi Hyun Bae, 1,2,3 Do Seon Song, 1,2,3 Myeong Jun Song, 1,4 Woo Jin Chung, 1,5
Comparison of efficacy between hepatic arterial infusion chemotherapy and sorafenib in advanced hepatocellular carcinoma with portal vein tumor thrombosis 1,2,3 Si Hyun Bae, 1,2,3 Do Seon Song, 1,2,3 Myeong
More informationHCC with Intrahepatic Portal vein Tumour Should Be Treated by Systemic Therapy Rather Than Transarterial Therapy (Pros)
HCC with Intrahepatic Portal vein Tumour Should Be Treated by Systemic Therapy Rather Than Transarterial Therapy (Pros) Yi-Hsiang Huang, MD, Ph.D. Professor, Division of Gastroenterology & Hepatology,
More informationHow to evaluate tumor response? Yonsei University College of Medicine Kim, Beom Kyung
How to evaluate tumor response? Yonsei University College of Medicine Kim, Beom Kyung End points in research for solid cancers Overall survival (OS) The most ideal one, but requires long follow-up duration
More informationHepatobiliary Malignancies Retrospective Study at Truman Medical Center
Hepatobiliary Malignancies 206-207 Retrospective Study at Truman Medical Center Brandon Weckbaugh MD, Prarthana Patel & Sheshadri Madhusudhana MD Introduction: Hepatobiliary malignancies are cancers which
More informationMultidisciplinary Treatment Strategies for Primary and Metastatic Liver Cancers
Multidisciplinary Treatment Strategies for Primary and Metastatic Liver Cancers Ching-Wei D. Tzeng, M.D. Assistant Professor Surgical Oncology University of Kentucky Markey Cancer Center Affiliate Network
More informationIn- and exclusion criteria
In- and exclusion criteria Kerstin Schütte Department of Gastroenterology, Hepatology and Infectious Diseases University of Magdeburg Overview: Study population Inclusion criteria I - General criteria
More informationCelsion Symposium New Paradigms in HCC Staging: HKLC vs. BCLC Staging
Celsion Symposium New Paradigms in HCC Staging: HKLC vs. BCLC Staging Ronnie T.P. Poon, MBBS, MS, PhD Chair Professor of Hepatobiliary and Pancreatic Surgery Chief of Hepatobiliary and Pancreatic Surgery
More informationSIRTEX Lunch Symposium, Cebu, 23 Nov Dr. Stephen L. Chan Department of Clinical Oncology The Chinese University of Hong Kong
SIRTEX Lunch Symposium, Cebu, 23 Nov 2013 Dr. Stephen L. Chan Department of Clinical Oncology The Chinese University of Hong Kong I will not talk on Mechanism of SIRT Data on efficacy of SIRT Epidemiology
More informationTACE: coming of age?
Invasive procedures in the diagnosis and treatment of liver diseases: focal lesions F.Farinati Gastroenterologia, Padova TACE: coming of age? AISF 2005 TACE: LEVELS OF EVIDENCE Degree of certainty Methodology
More information100% pure beta emitter Decays to zirconium-90 Physical half-life of 64.1 hours (2.67 days) 94% of radiation delivered within 11 days
100% pure beta emitter Decays to zirconium-90 Physical half-life of 64.1 hours (2.67 days) 94% of radiation delivered within 11 days TheraSphere [US package insert]. Surrey, UK: Biocompatibles UK Ltd,
More informationTranscatheter Arterial Chemoembolization (TACE) to Treat Primary or Metastatic Liver Malignancies. Original Policy Date
MP 8.01.09 Transcatheter Arterial Chemoembolization (TACE) to Treat Primary or Metastatic Liver Malignancies Medical Policy Section Therapy Issue 12/2013 Original Policy Date 12/2013 Last Review Status/Date
More informationTranscatheter hepatic arterial chemoembolization may be considered medically necessary to
Original Issue Date (Created): July 1, 2002 Most Recent Review Date (Revised): September 24, 2013 Effective Date: November 1, 2013 I. POLICY Hepatocellular carcinoma Transcatheter hepatic arterial chemoembolization
More informationHepatocellular Carcinoma. Markus Heim Basel
Hepatocellular Carcinoma Markus Heim Basel Outline 1. Epidemiology 2. Surveillance 3. (Diagnosis) 4. Staging 5. Treatment Epidemiology of HCC Worldwide, liver cancer is the sixth most common cancer (749
More informationSaudi Gastroenterology Association Guidelines for the Diagnosis and Management of Hepatocellular Carcinoma: Summary of Recommendations
Special Communication Saudi Gastroenterology Association Guidelines for the Diagnosis and Management of Hepatocellular Carcinoma: Summary of Guidelines Editors: Ayman A Abdo, Huda Al Abdul Karim, Turki
More informationin Hepatocellular Carcinoma
in Hepatocellular Carcinoma The following summarises the key data supporting the use of SIR-Spheres Y-90 resin microspheres in the treatment of primary liver cancer due to hepatocellular carcinoma (HCC):
More informationTranscatheter Arterial Chemoembolization to Treat Primary or Metastatic Liver Malignancies
Transcatheter Arterial Chemoembolization to Treat Primary or Metastatic Liver Malignancies Policy Number: 8.01.11 Last Review: 6/2018 Origination: 8/2005 Next Review: 6/2019 Policy Blue Cross and Blue
More informationThe Role of Interventional Radiology (Locoregional
The Role of Interventional Radiology (Locoregional therapies) in HCC Richard Owen MB, MRCP, FRCR Interventional Radiology, Associate Professor University of Alberta Aldo Montana-Loza MD, FRCPC Hepatology
More informationHepatocellular carcinoma: from guidelines to individualized treatment
AISF 2012 Rome, 22-24 February 2012 Hepatocellular carcinoma: from guidelines to individualized treatment A.D. 1088 Luigi Bolondi Professor of Medicine, Chairman Department of Digestive Diseases and Internal
More informationRadiofrequency Ablation of Primary or Metastatic Liver Tumors
Radiofrequency Ablation of Primary or Metastatic Liver Tumors Policy Number: 7.01.91 Last Review: 9/2018 Origination: 2/1996 Next Review: 9/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC)
More informationHCC Imaging and Advances in Locoregional Therapy. David S. Kirsch MD Ochsner Clinic Foundation
HCC Imaging and Advances in Locoregional Therapy David S. Kirsch MD Ochsner Clinic Foundation -Nothing to disclose Hepatic Imaging Primary imaging modalities include: US CT MR Angiography Nuclear medicine
More informationOptimal management of HCC: in Asia
Optimal management of HCC: in Asia Kwang-Hyub Han, MD Department of Internal Medicine, Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Korea Newly diagnosed HCC : > 70% occur
More informationRadiation Therapy for Liver Malignancies
Outline Radiation Therapy for Liver Malignancies Albert J. Chang, M.D., Ph.D. Department of Radiation Oncology, UCSF March 23, 2014 Rationale for developing liver directed therapies Liver directed therapies
More informationPaul Martin MD FACG. University of Miami
Paul Martin MD FACG University of Miami 1 Liver cirrhosis of any cause Chronic C o c hepatitis epat t s B Risk increases with Male gender Age Diabetes Smoking ~5% increase in HCV-related HCC between 1991-28
More informationdoi: /hepr Response Evaluation Criteria in Cancer of the Liver (RECICL) (2015 Revised version)
bs_bs_banner Hepatology Research 2016; 46: 3 9 doi: 10.1111/hepr.12542 Special Report Response Evaluation Criteria in Cancer of the Liver (RECICL) (2015 Revised version) Masatoshi Kudo, Kazuomi Ueshima,
More informationAdvances in percutaneous ablation and systemic therapies for hepatocellular carcinoma
Advances in percutaneous ablation and systemic therapies for hepatocellular carcinoma Paris Hepatology Congress 2019 Pierre Nahon Service d Hépatologie Hôpital Jean Verdier Bondy Université Paris 13 INSERM
More informationTranscatheter Arterial Chemoembolization (TACE) to Treat Primary or Metastatic Liver Malignancies
Transcatheter Arterial Chemoembolization (TACE) to Treat Primary or Metastatic Liver Malignancies Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its
More informationHepatocellular Carcinoma (HCC): Who Should be Screened and How Do We Treat? Tom Vorpahl MSN, RN, ACNP-BC
Hepatocellular Carcinoma (HCC): Who Should be Screened and How Do We Treat? Tom Vorpahl MSN, RN, ACNP-BC Objectives Identify patient risk factors for hepatocellular carcinoma (HCC) Describe strategies
More informationRecognizing the high prevalence of hepatocellular carcinoma
SPECIAL COMMUNICATION Saudi Gastroenterology Association Guidelines for the Diagnosis and Management of Hepatocellular Carcinoma: Summary of Recommendations Guidelines Editors: Ayman A Abdo, Huda Al Abdul
More informationTherapeutic Response Assessment and Endpoints in HCC
APASL HCC Conference, 2013 Cebu Therapeutic Response Assessment and Endpoints in HCC Ronnie T.P. Poon, MBBS, MS, PhD Chair Professor of Surgery Chief of Hepatobiliary and Pancreatic Surgery The University
More informationHepatocellular carcinoma (HCC) is the most common
Radioembolization for Hepatocellular Carcinoma Using Yttrium-90 Microspheres: A Comprehensive Report of Long-term Outcomes RIAD SALEM,*,, ROBERT J. LEWANDOWSKI,* MARY F. MULCAHY, AHSUN RIAZ,* ROBERT K.
More informationAlanine Amino Transferase (ALT) Among Blood Donors Visiting King Abdulaziz Medical City Blood Donor Center
Alanine Amino Transferase (ALT) Among Blood Donors Visiting King Abdulaziz Medical City Blood Donor Center Salem Alshimemeri 1, Mohammed Alshareef 1, Mohammed Sambas 1, Abdulrahman Alshareef 1, Waleed
More informationRadioembolization with Lipiodol for the Treatment of Hepatocellular Carcinoma and Liver Metastases
Radioembolization with Lipiodol for the Treatment of Hepatocellular Carcinoma and Liver Metastases Pr Francesco Giammarile CHLS Lyon Faculté de Lyon Sud «Aut tace aut loquere meliora silentio» Malignant
More informationInvited Re vie W. Analytical histopathological diagnosis of small hepatocellular nodules in chronic liver diseases
Histol Histopathol (1 998) 13: 1077-1 087 http://www.ehu.es/histoi-histopathol Histology and Histopathology Invited Re vie W Analytical histopathological diagnosis of small hepatocellular nodules in chronic
More informationEASL-EORTC Guidelines
Pamplona, junio de 2008 CLINICAL PRACTICE GUIDELINES: PARADIGMS IN MANAGEMENT OF HCC EASL-EORTC Guidelines Bruno Sangro Clínica Universidad de Navarra. CIBERehd. Pamplona, Spain Levels of Evidence according
More informationAddictive Benefit of Transarterial Chemoembolization and Sorafenib in Treating Advanced Stage Hepatocelluar Carcinoma: Propensity Analysis
Addictive Benefit of Transarterial Chemoembolization and Sorafenib in Treating Advanced Stage Hepatocelluar Carcinoma: Propensity Analysis Gwang Hyeon Choi, Ju Hyun Shim*, Min-Joo Kim, Min-Hee Ryu, Baek-Yeol
More informationCurrent Treatment of Colorectal Metastases. Dr. Thavanathan Surgical Grand Rounds February 1, 2005
Current Treatment of Colorectal Metastases Dr. Thavanathan Surgical Grand Rounds February 1, 2005 25% will have metastases at initial presentation 25-50% 50% will develop metastases later 40% of potentially
More informationRadioembolization for Primary and Metastatic Tumors of the Liver
Radioembolization for Primary and Metastatic Tumors of the Liver Policy Number: 8.01.43 Last Review: 8/2018 Origination: 8/2006 Next Review: 8/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue
More informationLiver metastases: treatment planning. PJ Valette
Liver metastases: treatment planning PJ Valette Liver metastases removal December 2010 April 2011 : after chemotherapy June 2011 : after resection of left lobe mets & portal embol. Sept 2011 : 1 year after
More informationUPDATE OF EASL CLINICAL PRACTICE GUIDELINES: MANAGEMENT OF HEPATOCELLULAR CARCINOMA*
UPDATE OF EASL CLINICAL PRACTICE GUIDELINES: MANAGEMENT OF HEPATOCELLULAR CARCINOMA* Dr. Catherine Frenette Medical Director of Liver Transplantation, Scripps Green Hospital, La Jolla, CA, USA May 2018
More informationProfile of Viral Hepatitis in Saudi Arabia
Profile of Viral Hepatitis in Saudi Arabia A. A. Alshabanat, R. B. Albacker, A. A. Basalama, A. A. Bin Salamah, A. S. Alfrayh Abstract The study was conducted to investigate the profile of hepatitis in
More informationSelective Internal Radiation Therapy (SIRT) in the multimodal approach to Hepatocellular Carcinoma
Selective Internal Radiation Therapy (SIRT) in the multimodal approach to Hepatocellular Carcinoma International Course on THERANOSTICS and MOLECULAR RADIOTHERAPY Brussels, 4 october 2017 Vincent Donckier
More informationHCC RADIOLOGIC DIAGNOSIS
UCSF Transplant 2010 THE BEFORE AND AFTER HEPATOCELLULAR CARCINOMA MANAGEMENT Francis Yao, M.D. Professor of Clinical Medicine and Surgery Medical Director, Liver Transplantation University of California,
More informationNew Insights: Systemic Therapy for Advanced Hepatocellular Carcinoma (HCC)
New Insights: Systemic Therapy for Advanced Hepatocellular Carcinoma (HCC) Thomas W.T. Leung Associate Director and Honorary Consultant Comprehensive Oncology Centre Hong Kong Sanatorium and Hospital Hong
More information9th Paris Hepatitis Conference
9th Paris Hepatitis Conference Paris, 12 January 2016 Treatment of hepatocellular carcinoma: beyond international guidelines Massimo Colombo Chairman Department of Liver, Kidney, Lung and Bone Marrow Units
More information蕾莎瓦 Nexavar 臨床試驗資料 (HCC 肝細胞癌 )
蕾莎瓦 Nexavar 臨床試驗資料 (HCC 肝細胞癌 ) 1 Sorafenib Improves Survival in Hepatocellular Carcinoma: Results of a Phase III Randomized, -Controlled Trial Josep M. Llovet, Sergio Ricci, Vincenzo Mazzaferro, Philip
More informationTreatment of Hepatocellular Carcinoma. Andrew J. Muir, MD MHS Division of Gastroenterology Duke University Medical Center
Treatment of Hepatocellular Carcinoma Andrew J. Muir, MD MHS Division of Gastroenterology Duke University Medical Center Epidemiology of HCC: world The 5 th most common cancer worldwide > 500, 000 new
More informationSIRT in the Management of Metastatic Neuroendocrine Tumors
SIRT in the Management of Metastatic Neuroendocrine Tumors Navesh K. Sharma, DO, PhD Assistant Professor, Departments of Radiation Oncology, Diagnostic Radiology and Nuclear Medicine Medical Director,
More informationTREATMENT FOR HCC AND CHOLANGIOCARCINOMA. Shawn Pelletier, MD
TREATMENT FOR HCC AND CHOLANGIOCARCINOMA Shawn Pelletier, MD Treatment for HCC Treatment strategies Curative first line therapy Thermal ablation vs Resection vs Transplant Other first line therapies TACE
More informationEmbolotherapy for Cholangiocarcinoma: 2016 Update
Embolotherapy for Cholangiocarcinoma: 2016 Update Igor Lobko,MD Chief, Division Vascular and Interventional Radiology Long Island Jewish Medical Center GEST 2016 Igor Lobko, M.D. No relevant financial
More informationStaging & Current treatment of HCC
Staging & Current treatment of HCC Dr.: Adel El Badrawy Badrawy; ; M.D. Staging & Current ttt of HCC Early stage HCC is typically silent. HCC is often advanced at first manifestation. The selective ttt
More informationThe Management of Advanced Stage Hepatocellular Carcinoma
The Management of Advanced Stage Hepatocellular Carcinoma Pierce K.H Chow MD PhD Professor, Duke-NUS Graduate Medical School Singapore Senior Consultant Surgeon, National Cancer Center Singapore Senior
More informationHepatocellular Carcinoma (HCC)
Title Slide Hepatocellular Carcinoma (HCC) Professor Muhammad Umar MBBS, MCPS, FCPS (PAK), FACG (USA), FRCP (L), FRCP (G), ASGE-M(USA), AGAF (USA) Chair & Professor of Medicine Rawalpindi Medical College
More informationDisclosure. Speaker name: Prof. Maciej Pech I have the following potential conflicts of interest to report:
Disclosure Speaker name: Prof. Maciej Pech I have the following potential conflicts of interest to report: Consulting Employment in industry Stockholder of a healthcare company Owner of a healthcare company
More information+ Radioembolization for ColoRectal Cancer Metastatic to the Liver
+ Radioembolization for ColoRectal Cancer Metastatic to the Liver Oct 4 th 2017 Alain Hendlisz, Institut Jules Bordet 1 st International Course on THERANOSTICS & MOLECULAR RADIOTHERAPY Indication and Rationale
More informationIMPLANTABLE BETA-EMITTING MICROSPHERES FOR TREATMENT OF MALIGNANT TUMORS
UnitedHealthcare Commercial Medical Policy IMPLANTABLE BETA-EMITTING MICROSPHERES FOR TREATMENT OF MALIGNANT TUMORS Policy Number: 2018T0445O Effective Date: February 1, 2018 Table of Contents Page INSTRUCTIONS
More informationMP Transcatheter Arterial Chemoembolization to Treat Primary or Metastatic Liver Malignancies
Medical Policy MP 8.01.11 BCBSA Ref. Policy: 8.01.11 Last Review: 07/25/2018 Effective Date: 07/25/2018 Section: Therapy Related Policies 7.01.75 Cryosurgical Ablation of Primary or Metastatic Liver Tumors
More informationStereotactic Body Radiotherapy (SBRT) For HCC T A R E K S H O U M A N P R O F. R A D I A T I O N O N C O L O G Y N C I, C A I R O U N I V.
Stereotactic Body Radiotherapy (SBRT) For HCC T A R E K S H O U M A N P R O F. R A D I A T I O N O N C O L O G Y N C I, C A I R O U N I V. Hepatocellular carcinoma (HCC), is a major health problem worldwide.
More informationFegato le)eratura ed esperienza clinica. A Guarneri
Fegato le)eratura ed esperienza clinica A Guarneri EASL EORTC Clinical Practice GuidelinesJ Hepatology 2012 HEPATOCELLULAR CARCINOMA Classic Radia*on-Induced Liver Disease (RILD) Clinical syndrome of
More informationStudy Objective and Design
Randomized, Open Label, Multicenter, Phase II Trial of Transcatheter Arterial Chemoembolization (TACE) Therapy in Combination with Sorafenib as Compared With TACE Alone in Patients with Hepatocellular
More informationAggressive Treatment of Performance Status 1 and 2 HCC Patients Significantly Improves Survival - an Egyptian Retrospective Cohort Study of 524 Cases
RESEARCH ARTICLE Aggressive Treatment of Performance Status 1 and 2 HCC Patients Significantly Improves Survival - an Egyptian Retrospective Cohort Study of 524 Cases Ashraf Omar Abdel Aziz 1, Dalia Omran
More informationLiver Directed Therapy for Hepatocellular Carcinoma
Liver Directed Therapy for Hepatocellular Carcinoma Anil K Pillai MD, FRCR, Associate Professor, Department of Radiology UT Houston Health Science Center, Houston, TX, United States. Hepatocellular cancer
More informationHepatic Arterial Therapy as a Bridge to Ablation or Transplant in the Treatment of Hepatocellular Carcinoma
Hepatic Arterial Therapy as a Bridge to Ablation or Transplant in the Treatment of Hepatocellular Carcinoma RUSSELL WARE FARMER, M.D.,* IVAN KRALJ, M.D., ALESSANDR VALDATA, M.D., JOSE URBANO, M.D., DANIEL
More informationConformal external beam radiation or selective internal radiation therapy a comparison of treatment outcomes for hepatocellular carcinoma
Original Article Conformal external beam radiation or selective internal radiation therapy a comparison of treatment outcomes for hepatocellular carcinoma Oluwadamilola T. Oladeru 1, Joseph A. Miccio 1,
More informationSection: Medicine Last Reviewed Date: July Policy No: 140 Effective Date: October 1, 2014
Medical Policy Manual Topic: Radioembolization for Primary and Metastatic Tumors of the Liver Date of Origin: December 2, 2010 Section: Medicine Last Reviewed Date: July 2014 Policy No: 140 Effective Date:
More informationHCC: Is it an oncological disease? - No
June 13-15, 2013 Berlin, Germany Prof. Oren Shibolet Head of the Liver Unit, Department of Gastroenterology Tel-Aviv Sourasky Medical Center and Tel-Aviv University HCC: Is it an oncological disease? -
More informationFive Years Comprehensive Experience in Proton Radiotherapy in PMRC Tsukuba
PTCOG 47 Jacksonville, Florida 2008.05.22 Five Years Comprehensive Experience in Proton Radiotherapy in PMRC Tsukuba Koji Tsuboi M.D., Ph.D. Proton Medical Research Center, University of Tsukuba, JAPAN
More informationRadioembolization with Yttrium-90 microspheres for patients with unresectable hepatocellular carcinoma
Original Article Radioembolization with Yttrium-90 microspheres for patients with unresectable hepatocellular carcinoma Munveer Singh Bhangoo 1, Diraj R. Karnani 1, Paul N. Hein 2, Huan Giap 3, Harry Knowles
More informationPortal Vein Invasion and the Role of Liver Directed Therapy. Matthew S Johnson MD FSIR Indiana University May 6, 2016
Portal Vein Invasion and the Role of Liver Directed Therapy Matthew S Johnson MD FSIR Indiana University May 6, 2016 Matthew Johnson, M.D., FSIR Stock: Endoshape Consultant/Advisory Board: Bayer, BTG,
More informationBridging and downstaging treatments for hepatocellular carcinoma in patients on the waiting list for liver transplantation
Online Submissions: http://www.wjgnet.com/esps/ bpgoffice@wjgnet.com doi:10.3748/wjg.v19.i43.7515 World J Gastroenterol 2013 November 21; 19(43): 7515-7530 ISSN 1007-9327 (print) ISSN 2219-2840 (online)
More information간암의다양한병기분류법 : 현재사용중인병기분류를중심으로. Kim, Beom Kyung
간암의다양한병기분류법 : 현재사용중인병기분류를중심으로 Kim, Beom Kyung Importance of staging system 환자의예후예측 적절한치료방법적용 ( 수술, 방사선, 항암..) 의료진간의 tumor burden 에대한적절한의사소통 향후연구및 clinical trial 시연구집단의성격에대한객관적기준제시 Requisites for good staging
More informationSIRT in Neuroendocrine Tumors
SIRT in Neuroendocrine Tumors Marnix G.E.H. Lam, MD PhD Professor of Nuclear Medicine AVL Amsterdam UMC Utrecht ENETS Center of Excellence, The Netherlands Disclosure of speaker s interests Consultant
More informationPrior Authorization Review Panel MCO Policy Submission
Prior Authorization Review Panel MCO Policy Submission A separate copy of this form must accompany each policy submitted for review. Policies submitted without this form will not be considered for review.
More informationRole of loco-regional treatment in the medical and surgical management strategy of metastatic colorectal cancer
Role of loco-regional treatment in the medical and surgical management strategy of metastatic colorectal cancer M Ducreux, MD, PhD Gustave Roussy Villejuif, FRANCE M Ducreux is a consultant to Biocompatibles
More informationDescription. Section: Surgery Effective Date: October 15, 2014 Subsection: Surgery Original Policy Date: December 7, 2011 Subject:
Last Review Status/Date: September 2014 Page: 1 of 20 Description In radiofrequency ablation (RFA), a probe is inserted into the center of a tumor and the noninsulated electrodes, which are shaped like
More informationLatest Developments in the Treatment of Hepatocellular Carcinoma
Latest Developments in the Treatment of Hepatocellular Carcinoma Roniel Cabrera, MD MS Associate Professor of Medicine Director of Hepatology and Medical Director of Liver Transplantation Division of Gastroenterology,
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE INTERVENTIONAL PROCEDURES PROGRAMME Interventional procedure overview of selective internal radiation therapy for unresectable primary intrahepatic Intrahepatic
More information